The United States Medicines Agency (FDA) on Thursday granted full authorization for the antiviral drug remdesivir for hospitalized COVID-19 patients, confirming the conditional authorization granted in May, according to its manufacturer Gilead.
• Read also: Vaccine: volunteer dies in AstraZeneca clinical trial
• Read also: Venezuela to start COVID-19 vaccine between December and January
Gilead announced that it had received authorization for the drug, under the Veklury brand, stressing that it was the only specific treatment against COVID-19 so authorized after a more rigorous and definitive verification procedure. However, other treatments have received authorizations for emergency use. Gilead’s stock on the New York Stock Exchange jumped 4% soon after the announcement.